Katherine A. Eade
Insider
First SEC filing: June 12, 2026 · Latest: June 12, 2026
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 9, 2026 | HBIO | A | 16,556 | · | · | 58,669 Direct | +39.31% | Acquired | (price as of 2026-10-02) |
| July 16, 2025 | HBIO | A | 110,000 | · | · | 421,126 Direct | +35.36% | Acquired | (price as of 2026-10-02) |
| May 21, 2024 | HBIO | A | 45,872 | · | · | 311,126 Direct | +17.29% | Acquired | (price as of 2026-10-02) |
| May 22, 2023 | HBIO | A | 25,554 | · | · | 265,254 Direct | +10.66% | Acquired | (price as of 2026-10-02) |
| May 24, 2022 | HBIO | A | 38,259 | · | · | 239,700 Direct | +18.99% | Acquired | (price as of 2026-10-02) |
| Jan. 1, 2022 | HBIO | A | 2,525 | · | · | 201,441 Direct | +1.27% | Acquired | (price as of 2026-10-02) |
| Dec. 28, 2021 | HBIO | A | 1,401 | · | · | 198,916 Direct | +0.71% | Acquired | (price as of 2026-10-02) |
| May 25, 2021 | HBIO | A | 14,400 | · | · | 197,515 Direct | +7.86% | Acquired | (price as of 2026-10-02) |
| Jan. 4, 2021 | HBIO | A | 14,200 | · | · | 183,115 Direct | +8.41% | Acquired | (price as of 2026-10-02) |
| June 18, 2020 | HBIO | A | 28,100 | · | · | 168,915 Direct | +19.96% | Acquired | (price as of 2026-10-02) |
| Jan. 2, 2020 | HBIO | A | 19,300 | · | · | 140,815 Direct | +15.88% | Acquired | (price as of 2026-10-02) |
| Aug. 9, 2019 | HBIO | P | 39,915 | $2.48 | $98,989 | 121,515 Direct | +48.92% | Acquired | -66.4% (price as of 2026-10-02) |
| Aug. 1, 2019 | HBIO | A | 1,100 | · | · | 81,600 Direct | +1.37% | Acquired | (price as of 2026-10-02) |
| May 23, 2019 | HBIO | A | 35,100 | · | · | 80,500 Direct | +77.31% | Acquired | (price as of 2026-10-02) |
| Jan. 2, 2019 | HBIO | A | 12,700 | · | · | 45,400 Direct | +38.84% | Acquired | (price as of 2026-10-02) |
| June 1, 2018 | HBIO | A | 1,200 | · | · | 32,700 Direct | +3.81% | Acquired | (price as of 2026-10-02) |
| May 24, 2018 | HBIO | A | 18,100 | · | · | 31,500 Direct | +135.07% | Acquired | (price as of 2026-10-02) |
| Jan. 2, 2018 | HBIO | A | 11,100 | · | · | 13,400 Direct | +482.61% | Acquired | (price as of 2026-10-02) |
| Nov. 1, 2017 | HBIO | A | 2,300 | · | · | 2,300 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 30, 2017 | HBIO | A | 87,600 | · | · | 87,600 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Oct. 30, 2017 | HBIO | Non-Qualified Stock Option (right to buy) | Common Stock, par value $0.01 per share | $3.33 | Oct. 30, 2027 | 87,600 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).